Trial results

$MLTX — sonelokimab

MoonLake Immunotherapeutics (MLTX) sonelokimab: trial results in psoriatic arthritis, 2027.

Research by Catalyst Intel

The catalyst

"Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol"

— MoonLake Immunotherapeutics, 8-K filed 2026-11-04 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

MLTX-SONELOKIMAB-2026

Company

MoonLake Immunotherapeutics

Kind

Trial results

Indication

psoriatic arthritis

Window

2027-01-01 – 2027-03-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.